Dec 2015 $7 M No. 5 $2 to $10 million 43
Aeolus Pharmaceuticals, Inc.: Raise no. 5, Dec 2015 × Investors in this round 43 investors had bought by the notice of Dec 18, 2015: 43 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $194,735
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Brian Day · Executive Officer David C. Cavalier · Executive Officer, Director JOHN McMANUS · Executive Officer Ken A. Bright · Executive Officer Amit A. Kumar · Director Chris A. Rallis · Director Jeffrey A. Scott · Director John M. Clerici · Director John M. Farah, Jr. · Director Mitchell D. Kaye · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · broker-dealer Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in AR, FL, IL, KS, NY, TX Newport Coast Securities, Inc. (CRD 16944) · broker-dealer Newport Coast Securities, Inc. (CRD 16944) · New York, New York Sold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY Signed by David C. Cavalier, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 18, 2015. Read the notice at the SEC .
equity, options SEC Feb 2013 $4 M No. 4 $2 to $10 million 17
Aeolus Pharmaceuticals, Inc.: Raise no. 4, Feb 2013 × Investors in this round 17 investors had bought by the notice of Mar 6, 2013: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice JOHN McMANUS · Executive Officer Russell Skibsted · Executive Officer Amit M. Kumar · Director Chris A. Rallis · Director David C. Cavalier · Director John M. Farah, Jr. · Director Joseph J. Krivulka · Director Michael E. Lewis · Director Peter D. Suzkak · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Russell Skibsted, Senior Vice President & Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 6, 2013. Read the notice at the SEC .
equity SEC Aug 2010 $1 M No. 3 Under $2 million 2
Aeolus Pharmaceuticals, Inc.: Raise no. 3, Aug 2010 × Investors in this round 2 investors had bought by the notice of Aug 19, 2010: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $2 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Brian L. Day · Executive Officer John L. Mcmanus · Executive Officer Amit L. Kumar · Director Chris L. Rallis · Director David L. Cavalier · Director John L. Farah · Director Joseph L. Krivulka · Director Michael L. Lewis · Director Peter L. Suzdak · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John L. Mcmanus, President and ceo. Source: SEC Form D, newest notice filed Aug 19, 2010. Read the notice at the SEC .
equity, options SEC Oct 2009 $3 M No. 2 $2 to $10 million 3
Aeolus Pharmaceuticals, Inc.: Raise no. 2, Oct 2009 × Investors in this round 3 investors had bought by the notice of Aug 9, 2010: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Brian L. Day · Executive Officer John L. Mcmanus · Executive Officer Amit L. Kumar · Director Chris L. Rallis · Director David L. Cavalier · Director John L. Farah · Director Joseph L. Krivulka · Director Michael L. Lewis · Director Peter L. Suzdak · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John L. Mcmanus, President and ceo. Source: SEC Form D and 2 amendments, newest notice filed Aug 9, 2010. Read the notice at the SEC .
equity, options SEC Mar 2009 $2 M No. 1 Under $2 million 2
Aeolus Pharmaceuticals, Inc.: Raise no. 1, Mar 2009 × Investors in this round 2 investors had bought by the notice of Apr 6, 2009: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken $525,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in De People named in the notice Brian Day · Executive Officer John McManus · Executive Officer Michael McManus · Executive Officer Amit Kumar · Director Chris Rallis · Director David Cavalier · Director John Farah · Director Joseph Krivulka · Director Michael Lewis · Director Peter Suzdak · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Michael P. McManus, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Apr 6, 2009. Read the notice at the SEC .
equity, options SEC